Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131248 · ClinicalTrials.gov registry record · Phase 3
Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants
A Phase 3 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 3
- Development phase
- 18
- Enrollment target
NCT00131248 is a Phase 3 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 18 participants.
The verdict
NCT00131248, a Phase 3 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 18 participants
- Enrollment target
Study Summary
Study Question: In premature infants with apnea and/or bradycardia attributed to gastroesophageal reflux disease (GERD), does treatment with medications (acid blockers and motility agents), compared to placebo, reduce the frequency of apnea and bradycardia? Background: Many clinicians believe that apnea and bradycardia in preterm infants may be caused by gastroesophageal reflux (GER), however, studies have failed to demonstrate even a temporal association between episodes of GER and apnea. There have been no prospective randomized trials of treatment for GERD in preterm infants with apnea or other symptoms attributed to GER. Methods: A randomized, cross-over study will be performed. This cross-over design will provide the patient's clinician with unbiased information about the patient's response to treatment. The clinician can use this information in deciding whether or not to continue treatment after the two-week study period.
Interventions
- DRUG placebo
- DRUG Ranitidine
- DRUG Metaclopramide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-04 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00131248
The ClinicalTrials.gov registry entry for NCT00131248 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00131248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00131248 about?
NCT00131248 is a clinical study titled "Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants". Study Question: In premature infants with apnea and/or bradycardia attributed to gastroesophageal reflux disease (GERD), does treatment with medications (acid blockers and motility agents), compared to placebo, reduce the frequency of apnea and bradycardia? Background: Many clinicians believe that ...
What is the current status of trial NCT00131248?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 18 participants. The study started on 2004-04. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00131248?
The interventions under investigation include: placebo (DRUG), Ranitidine (DRUG), Metaclopramide (DRUG).
Who is sponsoring clinical trial NCT00131248?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.